Matthew Sykes
Stock Analyst at Goldman Sachs
(3.95)
# 538
Out of 4,810 analysts
190
Total ratings
49.62%
Success rate
8.16%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ICLR ICON Public Limited Company | Downgrades: Neutral | $250 → $200 | $145.29 | +37.66% | 3 | Mar 21, 2025 | |
| CRL Charles River Laboratories International | Downgrades: Neutral | $190 → $170 | $105.85 | +60.60% | 4 | Mar 21, 2025 | |
| FTRE Fortrea Holdings | Maintains: Neutral | $22 → $11 | $4.86 | +126.34% | 3 | Mar 4, 2025 | |
| GH Guardant Health | Maintains: Buy | $49 → $56 | $44.85 | +24.86% | 13 | Feb 21, 2025 | |
| WGS GeneDx Holdings | Maintains: Neutral | $70 → $80 | $102.22 | -21.74% | 11 | Feb 19, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Neutral | $1.75 → $1.5 | $1.27 | +18.11% | 5 | Feb 18, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $20 → $18 | $9.50 | +89.47% | 6 | Jan 28, 2025 | |
| NTRA Natera | Maintains: Buy | $160 → $190 | $151.74 | +25.21% | 13 | Jan 28, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $29 → $18 | $8.01 | +124.72% | 10 | Jan 28, 2025 | |
| NAUT Nautilus Biotechnology | Downgrades: Sell | $2.25 → $1.75 | $0.77 | +127.24% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $1.73 | +145.66% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $31.76 | +16.50% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $60 | $38.43 | +56.13% | 4 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $43.67 | +48.84% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $149.15 | +67.62% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $14 | $8.16 | +71.57% | 6 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $35 | $19.16 | +82.67% | 9 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $250 | $189.92 | +31.63% | 4 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $55 | $39.50 | +39.24% | 9 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $5.36 | +347.76% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,046.58 | +24.21% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $8.25 | +45.45% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $441.00 | +45.12% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $3.72 | +168.82% | 8 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $26 | $15.40 | +68.83% | 5 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $103.12 | +40.61% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $41.53 | - | 5 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $105 | $95.54 | +9.90% | 1 | Oct 31, 2023 |
ICON Public Limited Company
Mar 21, 2025
Downgrades: Neutral
Price Target: $250 → $200
Current: $145.29
Upside: +37.66%
Charles River Laboratories International
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $105.85
Upside: +60.60%
Fortrea Holdings
Mar 4, 2025
Maintains: Neutral
Price Target: $22 → $11
Current: $4.86
Upside: +126.34%
Guardant Health
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $44.85
Upside: +24.86%
GeneDx Holdings
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $102.22
Upside: -21.74%
Pacific Biosciences of California
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.27
Upside: +18.11%
NeoGenomics
Jan 28, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $9.50
Upside: +89.47%
Natera
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $151.74
Upside: +25.21%
Myriad Genetics
Jan 28, 2025
Maintains: Buy
Price Target: $29 → $18
Current: $8.01
Upside: +124.72%
Nautilus Biotechnology
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $0.77
Upside: +127.24%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $1.73
Upside: +145.66%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $31.76
Upside: +16.50%
Dec 5, 2024
Upgrades: Neutral
Price Target: $60
Current: $38.43
Upside: +56.13%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $43.67
Upside: +48.84%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $149.15
Upside: +67.62%
Oct 30, 2024
Maintains: Sell
Price Target: $16 → $14
Current: $8.16
Upside: +71.57%
Oct 16, 2024
Maintains: Buy
Price Target: $26 → $35
Current: $19.16
Upside: +82.67%
Jul 24, 2024
Maintains: Neutral
Price Target: $225 → $250
Current: $189.92
Upside: +31.63%
Jul 9, 2024
Maintains: Buy
Price Target: $45 → $55
Current: $39.50
Upside: +39.24%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $5.36
Upside: +347.76%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,046.58
Upside: +24.21%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $8.25
Upside: +45.45%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $441.00
Upside: +45.12%
Feb 29, 2024
Maintains: Buy
Price Target: $9 → $10
Current: $3.72
Upside: +168.82%
Dec 7, 2023
Maintains: Buy
Price Target: $23 → $26
Current: $15.40
Upside: +68.83%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $103.12
Upside: +40.61%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $41.53
Upside: -
Oct 31, 2023
Maintains: Buy
Price Target: $120 → $105
Current: $95.54
Upside: +9.90%